- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.04. | MaaT Pharma to Hold Annual General Meeting on May 28, 2024 | 173 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 15.04. | MaaT Pharma Presents Positive 18-month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event | 192 | Business Wire | Positive efficacy and safety results in 140 patients treated with MaaT013 in acute graft-versus-host disease (aGvHD) as part of the MaaT Pharma Early Access Program (EAP).
Gastrointestinal... ► Artikel lesen | |
| 09.04. | MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 225 | Business Wire | Article 223-16 of the General Regulations of the Financial Markets Authority
(AMF Autorité des Marchés Financiers)
Regulatory News:
MaaT Pharma(EURONEXT: MAAT the "Company"), a clinical-stage... ► Artikel lesen | |
| 08.04. | MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients' Responses to Immunotherapies | 286 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 05.04. | MaaT Pharma Announces Initiation of Coverage of its Stock by Gilbert Dupont/ Groupe Société Générale | 273 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 28.03. | MaaT Pharma Announces 2023 Annual Results and Provides a Business Overview | 225 | Business Wire | The DSMB, based on Phase 3 trial ARES preliminary data, concluded that MaaT013 has a favorable benefit/risk ratio with "high efficacy and low toxicity" in 3rd line aGvHD1. This evaluation confirms... ► Artikel lesen | |
| 21.03. | MaaT Pharma Strengthens Executive Team Appointing Jonathan Chriqui as Chief Business Officer | 239 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 19.03. | MaaT Pharma To Present New Preclinical Data at AACR for MaaT034 Aiming To improve Patients' Responses to Immunotherapies | 215 | Business Wire | Poster will present characterization of metabolites produced by MaaT034 and its immunomodulatory effects on host cells.
The new data strengthens previous promising findings shared at the... ► Artikel lesen | |
| 12.03. | MaaT Pharma Announces Long Term Follow-Up Data for MaaT013 in Early Access Program to be Presented at the Upcoming EBMT Conference | 263 | Business Wire | Oral presentation will highlight new data in Early Access Program (EAP) for patients with acute Graft-vs-Host Disease (aGvHD) treated with MaaT013.
This is the seventh year that MaaT Pharma's... ► Artikel lesen | |
| 08.03. | MaaT Pharma Releases its 2024 Financial Calendar | 148 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 08.03. | MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 87 | Business Wire | Article 223-16 of the General Regulations of the Financial Markets Authority (AMF Autorité des Marchés Financiers)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage... ► Artikel lesen | |
| 05.03. | MaaT Pharma indicates completion of Patient Recruitment for the Phase 2a Investigator-Sponsored Randomized Clinical Trial Evaluating MaaT013 in Combination with Immune Checkpoint Inhibitors in Metastatic Melanoma | 252 | Business Wire | Last patient randomized in Phase 2a PICASSO trial, sponsored by AP-HP in collaboration with MaaT Pharma, INRAE and Institut Gustave Roussy, evaluating MaaT013 in melanoma in combination with... ► Artikel lesen | |
| 29.02. | MaaT Pharma Announces Positive Review from the DSMB on the Ongoing Phase 1 Clinical Trial Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS) | 320 | Business Wire | Independent Data Safety and Monitoring Board (DSMB) recommended that the trial proceeds as planned without modifications.
MaaT033 has shown a good safety profile and was generally well... ► Artikel lesen | |
| 08.02. | MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 391 | Business Wire | Article 223-16 of the General Regulations of the Financial Markets Authority (AMF Autorité des Marchés Financiers)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage... ► Artikel lesen | |
| 22.01. | MaaT Pharma: Half-year Report on Liquidity Contract With the Brokerage Firm Kepler Cheuvreux | 331 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 08.01. | MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 372 | Business Wire | Article 223-16 of the General Regulations of the Financial Markets Authority (AMF Autorité des Marchés Financiers)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage... ► Artikel lesen | |
| 12.12.23 | MaaT Pharma to Host Virtual KOL Event on MaaT013 and MaaT033 Following ASH 2023 Presentations | 326 | Business Wire | The event will highlight positive efficacy and good safety results from 111 patients with acute graft-versus-host disease (aGvHD) treated with MaaT013 in the Early Access Program which have been... ► Artikel lesen | |
| 11.12.23 | MaaT Pharma Presents Positive Results with Lead Product MaaT013 and Provides Insights on Ongoing Phase 2b Trial with MaaT033 at ASH 2023 | 413 | Business Wire | Positive efficacy and good safety results from 111 patients with acute graft-versus-host disease (aGvHD) treated with MaaT013 in Early Access Program presented at 2023 ASH Meeting
Gastrointestinal... ► Artikel lesen | |
| 05.12.23 | MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 277 | Business Wire | Article 223-16 of the General Regulations of the Financial Markets Authority (AMF Autorité des Marchés Financiers)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage... ► Artikel lesen | |
| 30.11.23 | MaaT Pharma, Leader in Development of Microbiome-Based Therapies in Oncology, Awarded Government Funding for Clinical Development of MaaT033 as part of the France 2030 Plan | 378 | Business Wire | MaaT Pharma secures important funding in line with one of the goals under the Health Innovation 2030 Plan, the health component of 'France 2030', led by the Health Innovation Agency dedicated... ► Artikel lesen |
Seite:
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 20,410 | +1,80 % | Intellia Therapeutics, Inc.: Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024 | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,551 | +0,06 % | APEV, PACB and BILI are among premarket gainers | ||
| CENTOGENE | 0,450 | +10,17 % | Centogene N.V. - 6-K, Report of foreign issuer | ||
| ATAI LIFE SCIENCES | 1,864 | +0,22 % | atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights | Strategic investment in Beckley Psytech to accelerate the development of psychedelic-based therapies that fit within the two hour in-clinic treatment paradigm established by Spravato®Initial BPL-003... ► Artikel lesen | |
| BIOMERIEUX | 101,70 | +2,16 % | Biomerieux shares eye best day in 25 mths after better-than-expected Q1 | ||
| CYCLACEL | 2,080 | +42,47 % | Pre-market Movers: Cyclacel Pharmaceuticals, Marin Software, GeneDx, Sensata Technologies, Lichen China | INDIANAPOLIS (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.05 A.M. ET).In the Green Cyclacel Pharmaceuticals, Inc. (CYCC) is up... ► Artikel lesen | |
| SYROS PHARMACEUTICALS | 4,920 | +6,96 % | Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies... ► Artikel lesen | |
| GENUS | 20,200 | +2,54 % | Genus - Total Voting Rights | ||
| ATRECA | 0,155 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.03.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 28.03.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.03.2024ISIN NameGB00BZ2JBG28 REACT... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 2,300 | +3,60 % | XTL BIOPHARMACEUTICALS LTD - 6-K, Report of foreign issuer | ||
| ANAPTYSBIO | 22,800 | +14,57 % | AnaptysBio, Inc.: Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist, with top-line data anticipated by year-end 2024Enrollment ongoing for global Phase 2b trial... ► Artikel lesen | |
| ABIONYX PHARMA | 0,945 | -0,42 % | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX)
Market:... ► Artikel lesen | |
| MEIRAGTX | 4,500 | +2,74 % | MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates | - Company aligned with FDA on requirements for ongoing Phase 2 AQUAx2 clinical trial for Grade 2/3 radiation-induced xerostomia to be considered pivotal supporting potential BLA filing - Company... ► Artikel lesen | |
| METABOLIC EXPLORER | 0,140 | +0,14 % | XFRA 7ME: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| AKESO | 5,800 | 0,00 % | AKESO (09926): NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED HOLDERS - NOTICE OF PUBLICATION OF 2023 ANNUAL REPORT |
MAAT PHARMA SA gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 8,840 Euro und damit -0,67 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
